Today: 7 February 2026
Subscribe
Browse Category

Biotechnology News 24 December 2025 - 1 January 2026

INBS stock whipsaws after Intelligent Bio Solutions lines up $10 million funding

INBS stock whipsaws after Intelligent Bio Solutions lines up $10 million funding

Intelligent Bio Solutions shares jumped 132% to $9.53 before dropping 14% after-hours as the company announced a $10 million private placement and a new manufacturing deal with Syrma Johari MedTech. The placement, priced at $4.35 per share and warrants, is set well below the closing price. Volume hit 108 million shares. The company recently enacted a 1-for-10 reverse split after a Nasdaq minimum bid warning.
1 January 2026
··
BillionToOne (BLLN) stock slides 4% in thin year-end trade as investors look to January catalysts

BillionToOne (BLLN) stock slides 4% in thin year-end trade as investors look to January catalysts

BillionToOne shares fell 4% to $81.61 in thin trading on the last day of 2025, underperforming diagnostics peers. The company last reported third-quarter revenue of $83.5 million, up 117% year over year, and forecast full-year revenue of $293 million to $299 million. No new company disclosures appeared Wednesday. Management is set to present at the J.P. Morgan Healthcare Conference on Jan. 12.
31 December 2025
··
Cytokinetics stock jumps today as CYTK traders focus on Myqorzo launch and insider filing

Cytokinetics stock jumps today as CYTK traders focus on Myqorzo launch and insider filing

Cytokinetics shares climbed 3.7% to $63.63 Wednesday, bucking a weaker market as investors awaited Myqorzo’s U.S. launch in January. A Form 4 showed Chief Commercial Officer Andrew Callos sold 1,809 shares at $62.44 on Dec. 29 under a pre-set plan. The drug, approved this month, will be distributed with a REMS safety program. Investors are watching for pricing details and initial uptake.
31 December 2025
··
INBS stock surges 160% as Intelligent Bio Solutions strikes manufacturing deal targeting 40% cost cuts

INBS stock surges 160% as Intelligent Bio Solutions strikes manufacturing deal targeting 40% cost cuts

Intelligent Bio Solutions shares jumped 160% to $10.66 after announcing a manufacturing deal with Syrma Johari MedTech to scale production of its fingerprint drug-screening device. The company expects over 40% annual production cost savings and a 20-point gross margin boost. Trading volume hit 48.13 million shares, far above average. The stock traded between $5.62 and $11.52 after closing at $4.10 Tuesday.
31 December 2025
··
GRAIL stock drops in New York session as Galleri FDA filing timeline returns to focus

GRAIL stock drops in New York session as Galleri FDA filing timeline returns to focus

GRAIL shares dropped 3.3% to $84.95 Tuesday afternoon, extending a two-day slide. An Oregon Health & Science University release highlighted PATHFINDER 2 data and confirmed a first-quarter 2026 FDA submission for Galleri. Investors await management’s Jan. 12 update at the J.P. Morgan Healthcare Conference. The stock is down 7.2% since Friday’s close.
30 December 2025
··
Kymera Therapeutics (KYMR) stock falls today as biotech slips — what traders are watching

Kymera Therapeutics (KYMR) stock falls today as biotech slips — what traders are watching

Kymera Therapeutics shares fell 3% to $77.94 Tuesday afternoon, underperforming a 1.4% drop in the SPDR S&P Biotech ETF. The decline follows December’s $692 million equity raise and positive Phase 1b data for its STAT6 degrader KT-621. The stock traded about 9% below its recent $86 offering price. Investors are watching for updates on trial progress and cash burn ahead of 2026 milestones.
30 December 2025
··
Belite Bio stock swings to $170 and closes up nearly 7% as rally stays hot into year-end

Belite Bio stock swings to $170 and closes up nearly 7% as rally stays hot into year-end

NEW YORK, December 30, 2025, 05:26 ET — Premarket Belite Bio’s U.S.-listed shares were back in focus early Tuesday after the stock surged 6.7% in the prior session, swinging between $151.50 and $169.75 before ending at $165.29. Volume was 309,235 shares, above recent daily levels for the thinly traded biotech. StockAnalysis The move matters because Belite is trying to turn a rare-disease eye drug into a first-in-class launch, and the stock is now trading well above the $154 level at which it last sold new shares in a major December offering. In markets where liquidity thins out near year-end, sharp
30 December 2025
··
Praxis Precision Medicines stock jumps after FDA Breakthrough Therapy tag for tremor drug, BTIG lifts target

Praxis Precision Medicines stock jumps after FDA Breakthrough Therapy tag for tremor drug, BTIG lifts target

Praxis Precision Medicines shares jumped 13.25% to $304.58 Monday after the FDA granted Breakthrough Therapy Designation to ulixacaltamide for essential tremor. The company plans to file a New Drug Application in early 2026. BTIG raised its price target on PRAX to $843 from $507. The stock slipped about 1% in after-hours trading.
30 December 2025
···
Praxis Precision Medicines (PRAX) stock jumps 13% after FDA breakthrough designation for tremor drug

Praxis Precision Medicines (PRAX) stock jumps 13% after FDA breakthrough designation for tremor drug

Praxis Precision Medicines shares jumped 13% to $304.58 after the FDA granted Breakthrough Therapy Designation for ulixacaltamide in essential tremor. The stock traded between $318.08 and $275.00 during the session. Praxis said it plans to file a New Drug Application in early 2026. Analyst BTIG raised its price target on Praxis to $843.
30 December 2025
··
Mereo BioPharma stock crashes 88% after Phase 3 setrusumab miss sinks brittle-bone hopes

Mereo BioPharma stock crashes 88% after Phase 3 setrusumab miss sinks brittle-bone hopes

Mereo BioPharma shares plunged 87.65% to $0.29 after late-stage trials of setrusumab failed to meet the main fracture-rate goal in osteogenesis imperfecta. Both Phase 3 studies missed the primary endpoint, though bone mineral density improved and no new safety issues appeared. Analysts cut ratings as the company moved to reduce spending. Trading volume reached about 241 million shares.
30 December 2025
··
Regencell Bioscience Holdings Limited (NASDAQ: RGC) Stock: Shares Slide Into the Weekend After a 14% Drop—What to Watch Before Monday’s Open

Regencell Bioscience Holdings Limited (NASDAQ: RGC) Stock: Shares Slide Into the Weekend After a 14% Drop—What to Watch Before Monday’s Open

NEW YORK, Dec. 28, 2025, 3:41 a.m. ET — Market closed (weekend). Regencell Bioscience Holdings Limited (NASDAQ: RGC) heads into the weekend with traders focused on one thing: volatility. RGC stock finished the last regular session (Friday) sharply lower, while the broader market logged weekly gains in a quiet, holiday-shortened week—setting up a potentially jumpy start to the next session when U.S. equities reopen on Monday, Dec. 29. Investopedia RGC stock price today: where Regencell Bioscience stands after Friday’s slide RGC shares closed Friday at $21.16, down $3.44 (-13.98%) on the day. Trading was wide, with an intraday range of
28 December 2025
···
Moderna Stock (MRNA) News: Weekend Pause After Post-Holiday Drop, Analyst Targets, and What to Watch for Monday

Moderna Stock (MRNA) News: Weekend Pause After Post-Holiday Drop, Analyst Targets, and What to Watch for Monday

NEW YORK, Dec. 27, 2025, 8:12 p.m. ET — Market closed Moderna, Inc. (NASDAQ: MRNA) stock heads into the weekend with investors parsing a mix of technical read-throughs, biotech-sector screens, and diverging Wall Street targets after a sharp pullback in the final stretch of the holiday week. Shares of Moderna ended Friday’s regular session at $31.20, down 4.73% on the day, with the stock trading between $31.07 and $32.66. Extended-hours quotes Friday evening were modestly lower, with after-hours trading around $31.1 before markets went dark for the weekend. StockAnalysis+2Investing.com+2 With U.S. equity markets closed Saturday and Sunday, the next actionable
28 December 2025
··
CRISPR Therapeutics AG (CRSP) Stock: ARK Invest Adds Shares as Wall Street Weighs Zugo‑cel Data, Insider Sale, and 2026 Catalysts

CRISPR Therapeutics AG (CRSP) Stock: ARK Invest Adds Shares as Wall Street Weighs Zugo‑cel Data, Insider Sale, and 2026 Catalysts

NEW YORK, Dec. 27, 2025, 4:58 p.m. ET — Market closed (U.S. equities are shut for the weekend) CRISPR Therapeutics AG (NASDAQ: CRSP) heads into the final trading stretch of 2025 with investors balancing two forces that often define biotech stocks: headline-driven momentum and long-duration fundamental risk. The stock finished the most recent regular session (Friday, Dec. 26) at $55.08, down 2.87%, after trading between $56.54 and $53.76. In after-hours trading, CRSP was last shown around $55.24 late Friday evening. StockAnalysis That Friday move came against a holiday-thinned tape on Wall Street. Reuters described the broader market session as light-volume
27 December 2025
··
Zai Lab Limited Stock (NASDAQ: ZLAB) Today: Pre‑Market Watchlist After China’s COBENFY Approval, NRDL Renewals, and Fresh Pipeline Catalysts

Zai Lab Limited Stock (NASDAQ: ZLAB) Today: Pre‑Market Watchlist After China’s COBENFY Approval, NRDL Renewals, and Fresh Pipeline Catalysts

New York — Friday, December 26, 2025, 9:08 a.m. ET. U.S. equities are not yet in the regular session as of this writing; the Nasdaq opens at 9:30 a.m. ET. Barron’s That timing matters today because Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) is entering the session with multiple company-specific catalysts on the board—most notably China’s approval of COBENFY for schizophrenia, plus updates tied to China’s National Reimbursement Drug List (NRDL) and progress in a key oncology program (zocilurtatug pelitecan, “zoci”). Business Wire Meanwhile, the broader market backdrop is very “holiday week”: thin liquidity, a post‑Christmas reset, and investors still
26 December 2025
···
Edgewise Therapeutics (EWTX) Stock Surges on EDG-7500 Safety Update as Wall Street Prepares to Reopen After Christmas

Edgewise Therapeutics (EWTX) Stock Surges on EDG-7500 Safety Update as Wall Street Prepares to Reopen After Christmas

As of 8:54 a.m. ET in New York on Friday, December 26, 2025, U.S. stock exchanges have not yet opened for the regular session (standard hours are 9:30 a.m. to 4:00 p.m. ET). Nasdaq Edgewise Therapeutics, Inc. (NASDAQ: EWTX) is in focus heading into the post-holiday session after the company delivered an encouraging clinical update for EDG-7500—its investigational therapy for hypertrophic cardiomyopathy (HCM)—that helped drive a sharp rally in the last session before Christmas. PR Newswire Where EWTX stock stands pre-market Market data tracked by MarketBeat shows EWTX closing at $27.38 on December 24 (the last regular session before Christmas
26 December 2025
···
Eli Lilly (LLY) Stock After Hours on Dec. 24, 2025: Christmas Eve Close, GLP‑1 Headlines, and What to Watch Before Markets Reopen

Eli Lilly (LLY) Stock After Hours on Dec. 24, 2025: Christmas Eve Close, GLP‑1 Headlines, and What to Watch Before Markets Reopen

Eli Lilly and Company (NYSE: LLY) wrapped up a holiday-shortened Christmas Eve session with a modest gain — and then drifted slightly lower in thin after-hours trading as investors digested a policy-heavy news cycle around GLP‑1 obesity medicines. With U.S. markets closed on Christmas Day (Thursday, Dec. 25, 2025) and set to reopen Friday (Dec. 26, 2025), today’s late tape is less about big price swings and more about positioning: where Lilly stands in the global obesity market, what Washington’s latest coverage model could mean for pricing and volume, and what catalysts are coming next. AP News Eli Lilly stock
24 December 2025
···
1 … 4 5 6 7 8 … 15

Stock Market Today

Toyota stock price rises on CEO shake-up and higher profit outlook as buyout deadline nears

Toyota stock price rises on CEO shake-up and higher profit outlook as buyout deadline nears

7 February 2026
Toyota shares rose 2% to 3,780 yen Friday after the company raised its full-year profit forecast and announced CFO Kenta Kon will replace CEO Koji Sato on April 1. Third-quarter net revenues climbed 6.8% to 38.087 trillion yen, but North America posted a 5.6 billion yen operating loss. Toyota’s U.S. ADRs closed up 2.9%. The tender offer for Toyota Industries shares closes Feb. 12.
HSBC share price bounces back after BoE split vote — what to watch before Feb 25 results

HSBC share price bounces back after BoE split vote — what to watch before Feb 25 results

7 February 2026
HSBC shares closed up 2.2% at £13.06 on Friday, reversing Thursday’s drop as traders weighed possible Bank of England rate cuts and awaited the bank’s annual results on Feb. 25. The FTSE 100 rose 0.6%, with major UK banks also gaining. HSBC is also preparing to cut some banker bonuses and push out underperformers amid a cost reset. Key UK, U.S., and euro zone economic data are due next week.
Go toTop